"CA-125 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A carbohydrate antigen that occurs in tumors of the ovary as well as in breast, kidney, and gastrointestinal tract tumors and normal tissue. While it is tumor-associated, it is not tumor-specific and may have a protective function against particles and infectious agents at mucosal surfaces.
| Descriptor ID |
D018394
|
| MeSH Number(s) |
D12.776.395.560.631.050 D23.050.285.050.225 D23.050.550.325.225 D23.101.140.075.225
|
| Concept/Terms |
CA-125 Antigen- CA-125 Antigen
- Antigen, CA-125
- Antigen CA-125
- Antigen CA 125
- Mucin-16
- Mucin 16
- CA 125 Antigen
- Antigen, CA 125
|
Below are MeSH descriptors whose meaning is more general than "CA-125 Antigen".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Glycoproteins [D12.776.395]
- Mucoproteins [D12.776.395.560]
- Mucins [D12.776.395.560.631]
- CA-125 Antigen [D12.776.395.560.631.050]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Neoplasm [D23.050.285]
- Antigens, Tumor-Associated, Carbohydrate [D23.050.285.050]
- CA-125 Antigen [D23.050.285.050.225]
- Epitopes [D23.050.550]
- Antigens, Tumor-Associated, Carbohydrate [D23.050.550.325]
- CA-125 Antigen [D23.050.550.325.225]
- Biomarkers [D23.101]
- Biomarkers, Tumor [D23.101.140]
- Antigens, Tumor-Associated, Carbohydrate [D23.101.140.075]
- CA-125 Antigen [D23.101.140.075.225]
Below are MeSH descriptors whose meaning is more specific than "CA-125 Antigen".
This graph shows the total number of publications written about "CA-125 Antigen" by people in this website by year, and whether "CA-125 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 |
| 1996 | 3 | 2 | 5 |
| 1997 | 1 | 3 | 4 |
| 1998 | 3 | 3 | 6 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 2 | 3 |
| 2001 | 1 | 3 | 4 |
| 2002 | 3 | 3 | 6 |
| 2003 | 2 | 4 | 6 |
| 2004 | 3 | 3 | 6 |
| 2005 | 3 | 1 | 4 |
| 2006 | 3 | 1 | 4 |
| 2007 | 2 | 5 | 7 |
| 2008 | 2 | 5 | 7 |
| 2009 | 1 | 3 | 4 |
| 2010 | 3 | 5 | 8 |
| 2011 | 5 | 6 | 11 |
| 2012 | 3 | 2 | 5 |
| 2013 | 2 | 2 | 4 |
| 2014 | 4 | 2 | 6 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 2 | 4 |
| 2017 | 4 | 0 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 5 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "CA-125 Antigen" by people in Profiles.
-
Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework. J Natl Cancer Inst. 2024 Nov 01; 116(11):1798-1806.
-
Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. JAMA Netw Open. 2024 02 05; 7(2):e240260.
-
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor. J Clin Oncol. 2024 Apr 10; 42(11):1301-1310.
-
Normal Risk Ovarian Screening Study: 21-Year Update. J Clin Oncol. 2024 Apr 01; 42(10):1102-1109.
-
Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer. Br J Cancer. 2024 Mar; 130(5):861-868.
-
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. Gynecol Oncol. 2023 03; 170:300-308.
-
A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses. Clin Cancer Res. 2022 11 01; 28(21):4669-4676.
-
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022 12 01; 40(34):3965-3974.
-
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.
-
Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71.